Friday, March 11, 2016

XALKORI® (crizotinib) Approved by U.S. FDA for the Treatment of Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer

… patients with
metastatic non-small cell lung cancer (NSCLC) whose tumors are
ROS1-positive … for metastatic ROS1-positive non-small cell
lung cancer represents another significant step forward … investigator. “As with ALK-positive lung
cancer, ROS1-positive lung cancer defines a distinct subset of …

No comments:

Post a Comment